NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080223920

Registered date:01/06/2018

Basic Information

Recruitment status completed
Health condition(s) or Problem(s) studied
Date of first enrollment12/07/2018
Target sample size780
Countries of recruitmentJapan,North America,Europe
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Lenvatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Paclitaxel, Doxorubicin Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material :

Outcome(s)

Primary Outcomeefficacy efficacy
Secondary Outcomeefficacy efficacy safety pharmacokinetics safety efficacy

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderFemale
Include criteria
Exclude criteria

Related Information

Contact

Public contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation
Scientific contact
Name
Address
Telephone -
E-mail JPCT@merck.com
Affiliation